Human Trials

Merck’s Keytruda plus chemotherapy meets OS and PFS goals in KEYNOTE-590 trial

Merck announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer.

Opdivo delivers significant OS and PFS benefits in CheckMate -649 trial

Bristol Myers Squibb (BMS) said that the phase 3 CheckMate -649 trial showed that the Opdivo (nivolumab) plus chemotherapy delivered significant overall and progression-free survival benefits in first-line treatment of gastric and esophageal cancers.

Merck reports new positive outcomes for KEYTRUDA in stage 3 Melanoma trial

Merck announced new and updated findings from the Phase 3 EORTC1325/KEYNOTE-054 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.

PADCEV succeeds in confirmatory phase 3 trial in urothelial cancer

Seattle Genetics and Astellas Pharma said that PADCEV (enfortumab vedotin-ejfv) met the primary endpoint of overall survival (OS) in a confirmatory phase 3 trial in previously treated locally advanced or metastatic urothelial cancer.

CuraSen doses first subjects in phase 1 trial of CST-2032

CuraSen Therapeutics announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032, the company’s first proprietary compound intended for the treatment of neurodegenerative disease.

Melior Pharmaceuticals awarded grant for advancing pulmonary therapeutic in Covid-19 phase 2 clinical trial

Melior Pharmaceuticals has been awarded a grant from the Commonwealth of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program, which is designed to support rapid advancement of promising COVID-19 therapies.

Daiichi Sankyo initiates phase 2 study of patritumab deruxtecan in advanced colorectal cancer

Daiichi Sankyo Company announced that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), in patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least two prior lines of systemic therapy.

Baricitinib plus remdesivir reduces time to recovery in COVID-19 patients in NIAID-sponsored ACTT-2 trial

Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Covid-19 vaccine AZD1222 clinical trials resumed in the UK

Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.